Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24005505 | 0.82 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2TSHRNPSR1RECQL | |
| SCHEMBL25613561 | 0.82 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2TSHRNPSR1HTT | |
| SCHEMBL24775424 | 0.79 | HTR2A (0.40) | ALDH1A1SMN1; SMN2TSHRHTR6HTT | |
| SCHEMBL24775425 | 0.79 | HTR2A (0.40) | ALDH1A1SMN1; SMN2TSHRHTR6HTT | |
| SCHEMBL24775433 | 0.79 | HTR2A (0.40) | ALDH1A1SMN1; SMN2TSHRHTR6HTT | |
| SCHEMBL24775443 | 0.77 | RIPK1 (0.35) | — | |
| SCHEMBL25613563 | 0.76 | ALDH1A1 (0.42) | ALDH1A1TDO2KMT2APOLB | |
| SCHEMBL25613553 | 0.76 | DRD2 (0.35) | ALDH1A1HTR6POLB | |
| SCHEMBL24775439 | 0.76 | HRH3 (0.35) | — | |
| SCHEMBL24775160 | 0.74 | CHRNA7 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | ALDH1A1 3019/4885SMN1; SMN2 2369/4885TSHR 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.